Background Some retrospective studies have found that HIV-infected women have a higher mortality risk than men after adjusting for baseline characteristics, while others have not. Anemia is a known predictor of HIV-related mortality. We assessed whether anemia contributed to the sex difference in mortality in our cohort. Methods We conducted a retrospective cohort study among HIV-infected persons in care at the Comprehensive Care Center (Nashville, TN) between 1998 and 2009. Cox proportional hazards models compared time from first clinic visit to death and AIDS-defining events (ADE), adjusted for baseline characteristics with and without baseline hemoglobin. Results Of 3,633 persons, 879 (24%) were women. Women had lower median baseline hemoglobin compared to men: 12.4 g/dL (inter-quartile range (IQR) 11.3–13.4) vs. 14.4 (IQR 13.1–15.5), respectively (P<0.001). In multivariable models without hemoglobin, the risk of death was higher among women: hazard ratio (HR) 1.46 (95% confidence interval (CI) 1.17, 1.82; P = 0.001). In multivariable models with hemoglobin, the risk of death in women was diminished and no longer statistically significant: HR 1.2 (95% CI 0.93, 1.55; P = 0.17). The risk of ADE was higher among women in both models, but not statistically significant: HR 1.1 (95% CI 0.85–1.42; P = 0.46) in the model without hemoglobin and 1.11 (95% CI 0.82–1.48; P = 0.50) in the model with hemoglobin. Hemoglobin was a strong predictor of death: HR 0.88 per 1 g/dL increase (95% CI 0.83, 0.93; P<0.001). Conclusion In our study population of HIV-infected persons in care, women had lower baseline hemoglobin, and lower hemoglobin contributed to their higher risk of ADE and death.
References
[1]
Poundstone KE, Chaisson RE, Moore RD (2001) Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 15: 1115–1123.
[2]
Hessol NA, Kalinowski A, Benning L, Mullen J, Young M, et al. (2007) Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. Clin Infect Dis 44: 287–294.
[3]
Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garcia de Olalla P, et al. (2003) Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 17: 353–359.
[4]
Garcia de la Hera M, Ferreros I, del Amo J, Garcia de Olalla P, Perez Hoyos S, et al. (2004) Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 58: 944–950.
[5]
Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS (2007) Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials 8: 371–380.
[6]
Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, et al. (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362: 1267–1274.
[7]
Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, et al. (2001) Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 344: 720–725.
[8]
Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, et al. (2009) Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis 199: 991–998.
[9]
Braga P, Cardoso MR, Segurado AC (2007) Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil. AIDS Patient Care STDS 21: 321–328.
[10]
Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, et al. (2008) Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 13: 959–967.
[11]
Obirikorang C, Yeboah FA (2009) Blood haemoglobin measurement as a predictive indicator for the progression of HIV/AIDS in resource-limited setting. J Biomed Sci 16: 102.
[12]
Chene G, Easterbrook PJ, Juszczak E, Yu LM, Pocock SJ, et al. (1997) Long-term survival in patients with advanced immunodeficiency. AIDS 11: 209–216.
[13]
Berhane K, Karim R, Cohen MH, Masri-Lavine L, Young M, et al. (2004) Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr 37: 1245–1252.
[14]
Shah S, Smith CJ, Lampe F, Youle M, Johnson MA, et al. (2007) Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: relationships with gender. HIV Med 8: 38–45.
[15]
Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW (1998) Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 91: 301–308.
[16]
Moore RD, Keruly JC, Chaisson RE (1998) Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 19: 29–33.
[17]
Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, et al. (1999) Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 13: 943–950.
[18]
Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, et al. (2002) Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis 34: 260–266.
[19]
Tedaldi EM, Absalon J, Thomas AJ, Shlay JC, van den Berg-Wolf M (2008) Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 47: 441–448.
[20]
Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveilance care definition for AIDS among adolescents and adults. MMWR Recomm Rep 41(RR-17): 1–19.
[21]
Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, et al. (2006) Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 42: 554–561.
[22]
Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, et al. (2009) Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 51: 615–623.
[23]
Sarcletti M, Quirchmair G, Weiss G, Fuchs D, Zangerle R (2003) Increase of haemoglobin levels by anti-retroviral therapy is associated with a decrease in immune activation. Eur J Haematol 70: 17–25.
[24]
Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942–947.
